×
About 10,547 results

ALLMedicine™ Calcitonin Center

Research & Reviews  4,997 results

The PLGA nanoparticles for sustainable release of CGRP to ameliorate the inflammatory a...
https://doi.org/10.1080/10717544.2021.1902021
Drug Delivery; Wang F, Deng Y et. al.

May 7th, 2021 - The calcitonin gene-related peptide (CGRP) has been demonstrated relating to vascular and inflammatory regulations not only the nerve systems. As the anti-inflammation factor and the most potent vasodilator, the CGRP holds therapeutic potentials f...

Evaluation of a Pharmacy-Driven Calcitonin Protocol for Treating Hypercalcemia in Hospi...
https://doi.org/10.1177/08971900211013187
Journal of Pharmacy Practice; Marte F, Sanchez M et. al.

May 6th, 2021 - The dramatic increase in the acquisition cost of injectable calcitonin led to creating a pharmacy-driven calcitonin protocol to improve the appropriate use of calcitonin and other treatment modalities for hypercalcemia. This study aimed to charact...

Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered w...
https://doi.org/10.1007/s40261-021-01034-5 10.1146/annurev-physiol-030212-183717 10.1212/01.wnl.0000252808.97649.21 10.1111/head.12878 10.1186/1129-2377-15-2 10.1177/2514183X18823377 10.1111/head.12550 10.1111/j.1468-2982.2008.01819.x 10.1016/S0140-6736(19)32504-8 10.1016/S1474-4422(20)30234-9 10.1002/jcph.1610 10.1016/0006-2952(96)85085-4
Clinical Drug Investigation; Boinpally R, Spaventa J et. al.

May 5th, 2021 - Atogepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist in development for preventive treatment of migraine. To evaluate potential pharmacokinetic drug-drug interactions (DDIs), safety and tolerability of atogepant co-admin...

A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in H...
https://doi.org/10.1002/cpdd.940
Clinical Pharmacology in Drug Development; Boinpally R, McNamee B et. al.

May 4th, 2021 - Atogepant is a selective, oral calcitonin gene-related peptide receptor antagonist in development for preventive treatment of migraine. This randomized, double-blind, phase 1 crossover study evaluated the cardiac repolarization effect of a single ...

Esophageal Mucosa Innervation in Children With Nonerosive Reflux Disease.
https://doi.org/10.14309/ajg.0000000000001286
The American Journal of Gastroenterology; Nikaki K, Lee C et. al.

Apr 30th, 2021 - Esophageal mucosa innervation in adults with nonerosive reflux disease (NERD) is more superficial compared with healthy volunteers. We delineated the esophageal mucosal innervation in pediatric NERD and controls. Distal and proximal pediatric esop...

see more →

Guidelines  3 results

European headache federation guideline on the use of monoclonal antibodies acting on th...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734227
The Journal of Headache and Pain; Sacco S, Bendtsen L et. al.

Jan 17th, 2019 - Monoclonal antibodies acting on the calcitonin gene-related peptide or on its receptor are new drugs to prevent migraine. Four monoclonal antibodies have been developed: one targeting the calcitonin gene-related peptide receptor (erenumab) and thr...

Consensus on management of advanced medullary thyroid carcinoma on behalf of the Workin...
https://doi.org/10.1007/s12094-015-1465-x
Clinical & Translational Oncology : Official Publication ... Grande E, Santamaría Sandi J et. al.

Dec 21st, 2015 - Of all thyroid cancers, <5 % are medullary (MTC). It is a well-characterized neuroendocrine tumor arising from calcitonin-secreting C cells, and RET gene plays a central role on its pathogeny. The electronic search was conducted using MEDLINE (Pub...

The treatment of symptomatic osteoporotic spinal compression fractures.
https://doi.org/10.5435/00124635-201103000-00007
The Journal of the American Academy of Orthopaedic Surgeons; Esses SI, McGuire R et. al.

Mar 3rd, 2011 - This clinical practice guideline is based on a series of systematic reviews of published studies on the treatment of symptomatic osteoporotic spinal compression fractures. Of 11 recommendations, one is strong; one, moderate; three, weak; and six, ...

see more →

Drugs  35 results see all →

Clinicaltrials.gov  5,221 results

The PLGA nanoparticles for sustainable release of CGRP to ameliorate the inflammatory a...
https://doi.org/10.1080/10717544.2021.1902021
Drug Delivery; Wang F, Deng Y et. al.

May 7th, 2021 - The calcitonin gene-related peptide (CGRP) has been demonstrated relating to vascular and inflammatory regulations not only the nerve systems. As the anti-inflammation factor and the most potent vasodilator, the CGRP holds therapeutic potentials f...

Evaluation of a Pharmacy-Driven Calcitonin Protocol for Treating Hypercalcemia in Hospi...
https://doi.org/10.1177/08971900211013187
Journal of Pharmacy Practice; Marte F, Sanchez M et. al.

May 6th, 2021 - The dramatic increase in the acquisition cost of injectable calcitonin led to creating a pharmacy-driven calcitonin protocol to improve the appropriate use of calcitonin and other treatment modalities for hypercalcemia. This study aimed to charact...

Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered w...
https://doi.org/10.1007/s40261-021-01034-5 10.1146/annurev-physiol-030212-183717 10.1212/01.wnl.0000252808.97649.21 10.1111/head.12878 10.1186/1129-2377-15-2 10.1177/2514183X18823377 10.1111/head.12550 10.1111/j.1468-2982.2008.01819.x 10.1016/S0140-6736(19)32504-8 10.1016/S1474-4422(20)30234-9 10.1002/jcph.1610 10.1016/0006-2952(96)85085-4
Clinical Drug Investigation; Boinpally R, Spaventa J et. al.

May 5th, 2021 - Atogepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist in development for preventive treatment of migraine. To evaluate potential pharmacokinetic drug-drug interactions (DDIs), safety and tolerability of atogepant co-admin...

A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in H...
https://doi.org/10.1002/cpdd.940
Clinical Pharmacology in Drug Development; Boinpally R, McNamee B et. al.

May 4th, 2021 - Atogepant is a selective, oral calcitonin gene-related peptide receptor antagonist in development for preventive treatment of migraine. This randomized, double-blind, phase 1 crossover study evaluated the cardiac repolarization effect of a single ...

Esophageal Mucosa Innervation in Children With Nonerosive Reflux Disease.
https://doi.org/10.14309/ajg.0000000000001286
The American Journal of Gastroenterology; Nikaki K, Lee C et. al.

Apr 30th, 2021 - Esophageal mucosa innervation in adults with nonerosive reflux disease (NERD) is more superficial compared with healthy volunteers. We delineated the esophageal mucosal innervation in pediatric NERD and controls. Distal and proximal pediatric esop...

see more →

News  291 results

Safety Profile for Novel CGRP Beats Standard of Care
https://www.medscape.com/viewarticle/949816

Apr 22nd, 2021 - Atogepant, an oral, small-molecule, calcitonin gene–related peptide receptor antagonist that's been in development as a preventive treatment for chronic migraine, has been found to have fewer side effects and similar hepatic function profile to st...

Intranasal Third-Generation CGRP Effective for Acute Migraine
https://www.medscape.com/viewarticle/949517

Apr 18th, 2021 - Intranasal zavegepant, a third-generation calcitonin gene-related peptide (CGRP) receptor agonist, is effective and well tolerated in the treatment of acute migraine, new research shows. In a randomized dose-ranging, placebo-controlled, phase 2/3 ...

CGRP May Offer Both Migraine Treatment and Prevention
https://www.medscape.com/viewarticle/943042

Dec 21st, 2020 - Rimegepant (Nurtec ODT), the first calcitonin gene–related peptide (CGRP) receptor antagonist approved in the United States for the acute treatment of migraine, may help prevent migraine headaches as well. In a phase 2/3 study, oral rimegepant was...

CGRPs Promising for Prevention of Chronic Cluster Headache
https://www.staging.medscape.com/viewarticle/937760

Sep 20th, 2020 - Treatment with calcitonin gene-related peptide (CGRP) monoclonal antibodies may reduce the frequency of chronic cluster headache (CCH) attacks in patients with an inadequate response to other preventive medications, new research shows. In findings...

CGRPs Promising for Prevention of Chronic Cluster Headache
https://www.medscape.com/viewarticle/937760

Sep 20th, 2020 - Treatment with calcitonin gene-related peptide (CGRP) monoclonal antibodies may reduce the frequency of chronic cluster headache (CCH) attacks in patients with an inadequate response to other preventive medications, new research shows. In findings...

see more →